Related by context. All words. (Click for frequent words.) 75 postmenopausal women 75 pre menopausal 73 post menopausal 69 premenopausal 66 postmenopausal 63 premenopausal breast cancer 63 perimenopausal women 62 polycystic ovary syndrome PCOS 62 folate intake 62 oophorectomy 62 tibolone 61 anovulatory infertility 61 undergone hysterectomy 61 menopausal women 60 vertebral fracture 60 lipid lowering therapy 60 bilateral oophorectomy 60 calcium supplementation 60 postmenopausal hormone therapy 60 folate supplementation 60 GnRH agonists 60 testosterone supplementation 60 menopausal hormone therapy 60 androgen deficiency 59 postmenopausal breast cancer 59 subclinical hypothyroidism 59 dietary calcium intake 59 elevated CRP 59 hypogonadal men 59 endometrial cancer 59 hip BMD 59 estrogen therapy 59 LUTS 59 nonpregnant women 59 CARDIA 59 hormone therapy estrogen 59 beta blocker therapy 59 hydroxyvitamin D levels 59 estrogen progestin therapy 59 urinary tract symptoms LUTS 58 vasomotor symptoms 58 chronic prostatitis 58 hypogonadal 58 HSDD 58 atypical hyperplasia 58 serum vitamin D 58 irregular menstrual cycles 58 MetS 58 nondepressed 58 liver transplant recipients 58 endometrial hyperplasia 58 cardiovascular mortality 58 osteopenic 58 parous women 58 estrogen receptor negative 58 symptomatic fibroids 58 breast carcinoma 57 colorectal adenoma 57 BRCA1 mutations 57 endometriosis ovarian cysts 57 nulliparous women 57 menopausal symptoms 57 Young Adults CARDIA 57 postmenopausal hormones 57 recurrent VTE 57 vaginal atrophy 57 VADT 57 Postmenopausal Women 57 endometrial carcinoma 57 undergone hysterectomies 57 hormone therapy HT 57 ovulation induction 57 conjugated equine estrogen 57 oral bisphosphonates 57 substudy 57 Screening Trial 57 gallstone disease 57 lobular cancer 57 distal colon cancer 57 anastrozole 57 mammographic density 56 hormone receptor positive 56 spontaneous preterm delivery 56 serum testosterone 56 decreased libido 56 glycemic diet 56 BRCA mutations 56 Digital Mammographic Imaging 56 lamotrigine 56 colorectal adenomas 56 thyrotropin levels 56 estradiol 56 Leitzmann 56 obese adolescents 56 breast tenderness 56 endometrial cancers 56 urinary tract symptoms 56 calcium intake 56 polycystic ovary syndrome 56 ATACAND 56 secondary hypogonadism 56 SHBG levels 56 valproate 56 operable breast cancer 56 neurocognitive function 56 Hypoactive Sexual Desire Disorder 56 Subgroup analyzes 56 selenium intake 56 prospective cohort 56 BRCA gene mutations 56 transferrin saturation 56 estrogen 56 Calcium intake 56 leiomyomas 56 carotid IMT 56 bisphosphonate therapy 56 mild gestational diabetes 56 subclinical hyperthyroidism 55 androgen therapy 55 beta carotene supplements 55 axillary lymph nodes 55 thyroid hormone levels 55 cerebral microbleeds 55 amenorrhea 55 hypothalamic amenorrhea 55 phytoestrogen intake 55 contralateral breast cancer 55 aromatase inhibitors AIs 55 ovulatory infertility 55 atypia 55 epithelial ovarian cancer 55 obese postmenopausal 55 BRCA mutation carriers 55 lipid lowering medications 55 Prostate Lung Colorectal 55 N telopeptide 55 BRCA2 mutation carriers 55 statin therapy 55 tamoxifen 55 BRCA1 mutation carriers 55 STRIDE PD 55 CVD mortality 55 β blockers 55 serum selenium 55 androgen deprivation 55 adjuvant chemotherapy 55 Dietary Modification Trial 55 advanced adenomas 55 varicocele 55 BRCA mutation 55 naturally occurring estrogen 55 hormone therapy 55 thromboembolic events 55 Postmenopausal 55 undergone radical prostatectomy 55 nonvertebral fracture 55 vitamin D supplementation 55 normotensive 55 PMDD 55 estrogen receptor positive 55 prostate cancer CaP 55 hirsutism 55 serum estradiol 55 BRCA2 mutations 55 plasma folate 55 dysmenorrhea 55 RBC folate 55 serum lipid levels 54 placebo controlled trials 54 urinary symptoms 54 oestradiol 54 antihypertensive therapy 54 poorer prognosis 54 bone mineral 54 BRCA2 carriers 54 randomized clinical trials 54 underwent bariatric surgery 54 ovarian function 54 postmenopausal hormone 54 serum IGF 54 DMPA 54 fragility fracture 54 triglyceride concentrations 54 polyp recurrence 54 adiponectin levels 54 randomized controlled trial 54 elevated triglyceride levels 54 Premenopausal women 54 periprocedural MI 54 subfertility 54 desire disorder HSDD 54 solifenacin 54 coronary calcification 54 ductal breast cancer 54 pathologic fractures 54 CC genotype 54 NHANES III 54 tricyclic antidepressants 54 dysglycemia 54 menstrual irregularities 54 recurrent UTI 54 adenoma 54 serum uric acid 54 adjuvant radiotherapy 54 magnesium intake 54 subclinical atherosclerosis 54 coronary artery calcification 54 adiponectin 54 EBRT 54 beta carotene supplementation 54 serum calcium 54 loop diuretics 54 dose oral contraceptives 54 tumor histology 54 paricalcitol 54 nephron sparing surgery 54 atherogenic dyslipidemia 54 postmenopausal estrogen 54 premenstrual syndrome PMS 54 bisphosphonate 54 Epidemiologic studies 54 distant metastases 54 mild analgesics 54 chlamydial infection 54 symptomatic BPH 54 dietary calcium 54 Communities ARIC study 54 recurrent miscarriage 54 prepubertal 54 dietary fat 54 HGPIN 54 LNG IUS 54 elevated LDL cholesterol 54 slow metabolizers 54 preoperative chemotherapy 54 atypical fractures 54 zoledronic acid 54 estrogen deficiency 54 highest tertile 54 Prostate Cancer Prevention 54 postoperative mortality 54 localized prostate cancer 54 preventive mastectomy 54 colorectal cancer incidence 54 PCa 54 aldosterone antagonist 54 randomized trials 54 prednisone prednisolone 54 thyroid stimulating hormone 54 endogenous estrogen 54 primary ovarian insufficiency 54 salpingo oophorectomy 54 tamoxifen raloxifene 54 adjuvant radiation 54 systolic hypertension 54 teriparatide 54 antihypertensive medications 54 benign breast 54 adenoma recurrence 54 lignan intake 54 microalbuminuria 54 ALCL 53 CLA supplementation 53 nonfasting triglyceride levels 53 Adjuvant chemotherapy 53 androgen suppression 53 enlarged prostates 53 adrenal function 53 telomere lengths 53 retrograde ejaculation 53 HER2 positive cancers 53 undergoing radical prostatectomy 53 rosuvastatin 53 Netherlands Cohort Study 53 colorectal neoplasia 53 intravesical therapy 53 randomized controlled trials 53 multivariate adjustment 53 RLS sufferers 53 paclitaxel eluting stents 53 hypoactive sexual desire 53 femoral neck BMD 53 hydroxyvitamin D concentrations 53 androgen suppression therapy 53 carotid stenosis 53 Heavy menstrual bleeding 53 urinary calcium 53 Intrinsa 53 Framingham Offspring Study 53 oral contraceptive pills 53 thiazide diuretics 53 antioxidant supplementation 53 perioperative complications 53 thyroid nodules 53 hormone receptor negative 53 pCR 53 serum PSA 53 carotid atherosclerosis 53 relapsed ovarian cancer 53 Endometrial 53 fasting insulin 53 glitazones 53 randomized clinical 53 narcolepsy cataplexy 53 abdominal adiposity 53 oropharyngeal cancer 53 faulty BRCA genes 53 hot flushes 53 nondiabetic patients 53 LYSTEDA 53 iodine intake 53 bioavailable testosterone 53 hsCRP levels 53 comorbidity 53 bladder cancers 53 Screening Trial DMIST 53 umol L 53 serum cholesterol 53 Wactawski Wende 53 Oestrogen 53 denser breasts 53 overactive bladder symptoms 53 NATRECOR ® 53 #F FDG PET 53 cystectomy 53 protein excretion 53 irregular menses 53 preventive mastectomies 53 dyspareunia 53 estrogen metabolites 53 cinacalcet 53 thyroid dysfunction 53 follicular phase 53 serum triglycerides 53 cilostazol 53 prostate cancer PCa 53 DEXA scan 53 retrospective cohort 53 anovulation 53 ductal carcinomas 53 ovulatory cycles 53 hyperandrogenism 53 esophageal squamous cell carcinoma 53 cosmetic breast implants 53 genital ulcer disease 53 antiarrhythmic drug 53 serum concentrations 53 haemorrhagic stroke 53 menstrual irregularity 53 intensive statin therapy 53 stable angina 53 lymph node removal 53 Prostatitis 53 vitamin D inadequacy 53 abnormal mammograms 53 Sexual dysfunction 53 hormonal therapy 53 T1DM 53 ovarian hormones 53 heavy menstrual bleeding 53 basal cell nevus syndrome 53 intravenous bisphosphonates 53 undergoing hysterectomy 53 abnormal glucose tolerance 53 mycophenolate mofetil 53 CYPHER Stent 53 neoadjuvant 53 advanced adenoma 53 radical prostatectomy 53 vulvovaginal atrophy 53 Estradiol 53 knee osteoarthritis 53 biochemical markers 52 abdominal obesity 52 sentinel node biopsy 52 Postmenopausal women 52 estrogen pills 52 venous thromboembolism 52 singleton pregnancies 52 clinically localized prostate 52 CaP 52 degarelix 52 TZDs 52 lipid levels 52 hormone estradiol 52 mammographic breast density 52 Nutrition EPIC 52 invasive breast cancer 52 thrombocytopenic 52 KRAS status 52 elevated depressive symptoms 52 neoplasia PIN 52 cervical lesions 52 DAPT 52 leptin deficient mice 52 mineral density 52 Osteoporotic Fractures 52 thromboembolism 52 modifiable risk 52 placebo controlled clinical 52 hypopituitarism 52 T2DM 52 BRCA carriers 52 androgen deprivation therapy 52 mCRC patients 52 recurrent ovarian cancer 52 serum phosphate 52 strontium ranelate 52 rFVIIa 52 testicular germ cell 52 knee OA 52 albumin excretion rate 52 luteal phase 52 testosterone deficiency 52 screening colonoscopy 52 calcium intakes 52 tamoxifen therapy 52 chronic prostatitis chronic 52 microbleeds 52 patients undergoing CABG 52 dose ionizing radiation 52 MMSE scores 52 thromboembolisms 52 ovarian stimulation 52 metastatic prostate 52 endometrial 52 thromboprophylaxis 52 ginkgo biloba extract 52 premature menopause 52 fasting triglyceride levels 52 PSADT 52 homocysteine concentrations 52 serum calcium levels 52 androgen excess 52 DHEA supplementation 52 precocious puberty 52 hypertension diabetes mellitus 52 unstable angina UA 52 lipid abnormalities 52 aromatase inhibitor therapy 52 contralateral breast 52 nonvertebral fractures 52 uncomplicated pregnancies 52 hip fracture 52 dutasteride 52 lymph node involvement 52 retrospective cohort study 52 CARDIA study 52 treat menopausal symptoms 52 APTIVUS r 52 biochemical recurrence 52 lumbar spine BMD 52 erectile difficulties 52 glycated hemoglobin levels 52 prophylactic mastectomy 52 colorectal neoplasms 52 OAB symptoms 52 incidentalomas 52 Swedish Mammography Cohort 52 androgen ablation 52 invasive carcinoma 52 observational study 52 gestational hypertension 52 dietary glycemic index 52 postmenopausal osteoporosis 52 fluvastatin 52 coronary artery calcium 52 acrylamide intake 52 improves insulin sensitivity 52 lobular breast cancer 52 gonadotropins 52 elevated hsCRP 52 BMD measurements 52 atypical ductal hyperplasia 52 typical antipsychotics 52 nocturia 52 serum urate levels 52 endometriosis 52 antigen PSA 52 soy isoflavones 52 climacteric symptoms 52 fasting glucose levels 52 adjuvant therapy 52 oral bisphosphonate 52 nonmelanoma skin cancers 52 phytoestrogen 52 dietary intake 52 eribulin 52 venous thrombosis 52 hypertensive patients 52 ductal cancer 52 serum folate concentrations 52 sedentary postmenopausal 52 confidence interval #.#-#.# 52 Testosterone gel 52 urothelial cancer 52 depressive symptoms 52 calorie diets 52 bone resorption 52 menstrual bleeding 52 IV bisphosphonates 52 polycystic ovarian syndrome PCOS 52 ejaculatory dysfunction 52 progestin therapy 52 plasma lipid 52 osteoporotic 52 candesartan 52 progestins 52 hippocampal volume 52 Follicle Stimulating Hormone FSH 52 CHD mortality 52 estrogen receptor ER 52 folic acid intake 52 menopause 52 Progestin 52 nonalcoholic steatohepatitis NASH 52 estrone 52 adrenalectomy 52 surgically menopausal women 52 colorectal liver metastases 52 HER2 positive tumors 52 VTE prophylaxis 52 exemestane 52 Invasive Breast Cancer 52 Inhibin B 52 postmenopausal hormone replacement 52 abdominal hysterectomy 52 lasofoxifene 52 overt hypothyroidism 52 urinary oxalate 52 Cholesterol Levels SPARCL 52 breastfed infants 52 antihypertensive medication 52 triacylglycerol concentrations 52 GH deficient 52 prophylactic mastectomies 52 subtrochanteric 51 EGFR mutation 51 hormonal treatments 51 timepoint 51 F FDG PET 51 serum testosterone levels 51 coinfected patients 51 Insulin sensitivity 51 observational studies 51 Estrogen therapy 51 postmenopause 51 cranial irradiation 51 eplerenone 51 amenorrhoea 51 adiponectin concentrations 51 HIV seronegative 51 fibroids endometriosis 51 B7 H3 51 prescribed statins 51 Vitamin D supplements 51 FSAD 51 hydroxychloroquine 51 brain shrinkage 51 LHRH agonists 51 vascular dysfunction 51 dexamethasone Decadron 51 macrovascular disease 51 Stop Hypertension diet 51 postoperative atrial fibrillation 51 nondiabetic 51 urinary incontinence UI 51 vardenafil Levitra 51 body fatness 51 disorder HSDD 51 SORT OUT III 51 thyroxine 51 Papillary 51 specific antigen PSA 51 Triglyceride levels 51 CYP#D# inhibitor 51 abnormal Pap smears 51 proliferative diabetic retinopathy 51 Schaffir 51 onset atrial fibrillation 51 polycystic ovarian syndrome 51 dyslipidaemia 51 gestational diabetes mellitus 51 menstrual abnormalities 51 dietary intakes 51 glycemic load 51 osteopenia 51 iron deficient 51 parathyroidectomy 51 homocysteine levels 51 baseline HbA1c 51 cutaneous melanoma 51 atrophic gastritis 51 STEP BD 51 contralateral prophylactic mastectomy 51 venlafaxine Effexor 51 premenopause 51 aromatase inhibitor 51 dietary questionnaires 51 Radical prostatectomy 51 flutamide 51 Hypogonadism 51 macroalbuminuria 51 abdominal fat 51 nonfatal MI 51 dysmenorrhoea 51 ovaries removed 51 osteoporotic fractures 51 dose aspirin 51 postoperative AF 51 polycystic ovaries 51 abdominal ultrasounds 51 NATRECOR R 51 spontaneous preterm birth 51 coronary blockages 51 Taxus Stent 51 BRCA2 mutation 51 bisphosphonates 51 selenium supplementation 51 breast cancer recurrence 51 perimenopause 51 JoAnn Manson 51 prostate carcinoma 51 selenium supplements 51 gonococcal infections 51 randomized controlled 51 spine fractures 51 PLCO 51 rimonabant #mg 51 preeclamptic 51 APOE genotype 51 severe psoriasis 51 pregabalin 51 TT genotype 51 hypocaloric diet 51 pattern baldness 51 antiandrogens 51 Women Ischemia Syndrome 51 GBA mutations 51 Enlarged prostate 51 underwent radical prostatectomy 51 ARIXTRA 51 vitamin D insufficiency 51 serum leptin 51 estrogen progesterone 51 LDL cholesterol levels 51 plus medroxyprogesterone acetate 51 induce ovulation 51 screening mammography 51 antidepressant therapy 51 HNSCC 51 risedronate 51 aminotransferases 51 urinary albumin 51 menopausal symptom 51 Avandia Actos 51 nortriptyline 51 INTERHEART study 51 stone formers 51 relieving menopausal symptoms 51 BRAF mutation 51 TEAEs 51 breast lesions 51 perimenopausal 51 HIV HCV coinfected 51 Cochrane reviewers 51 RCTs 51 triglyceride levels 51 isoflavone supplements 51 cardiac toxicity 51 nondiabetics 51 histologically confirmed 51 prospective multicentre 51 statin medications 51 kidney transplant recipients 51 MGUS 51 Naive Patients 51 glandular tissue 51 myocardial infarction MI 51 sulphonylureas 51 Femara letrozole 51 metabolic syndrome MetS 51 Breast Cancer Risk 51 fluoxetine Prozac 51 serum PTH 51 squamous cell lung cancer 51 underwent prostatectomy 51 mIU L 51 metabolic parameters 51 metabolic syndrome 51 GnRH agonist 51 muscle dysmorphia 51 azoospermia 51 vitamin D intake 51 core needle biopsies 51 testicular tumors 51 menthol smokers 51 KRAS variant 51 menarche 51 d4T 51 hypertensives 51 serum folate 51 fructose diet 51 AVODART 51 mutated BRCA1 51 hormonal contraception 51 bisphosphonate drugs 51 inversely associated 51 anticholinergic drugs 51 glargine 51 asymptomatic carotid stenosis 51 highest quintile 51 locoregional recurrence 51 ovariectomy 51 heterozygotes 51 URTI 51 lobular involution 51 elevated triglycerides 51 Soy isoflavones 51 albuminuria 51 prognostic factors 51 serodiscordant couples 51 THIS STUDY 51 paroxysmal AF 51 estrogen progestin combination 51 Ovary removal 51 ALT flares 51 serum homocysteine 51 Benign prostatic hyperplasia BPH 51 hereditary hemochromatosis 51 prostatectomy 51 PSA velocity 51 prolactin levels 51 raloxifene Evista 51 HYVET 51 ximelagatran 50 CALGB # [001] 50 metabolic disturbances 50 posttreatment 50 mixed hyperlipidemia 50 EGFR mutations 50 comorbidities 50 hypercholesterolaemia 50 luteal 50 dose clopidogrel 50 androgenic hormones 50 abciximab 50 noncardiac 50 estrogen hormone therapy 50 endometrial thickness 50 liver resection 50 adenomatous 50 adjunctive ABILIFY 50 Clinical Endocrinology & 50 atorvastatin Lipitor 50 lipid parameters 50 perioperative mortality 50 prostate cancer CRPC 50 multicenter study 50 lipid profiles 50 metachronous 50 dietary folate intake 50 Androgens 50 folic acid supplement 50 SHBG 50 adenomatous polyps 50 nodal metastases 50 urolithiasis 50 probiotic supplementation 50 RAS inhibitors 50 osteoporotic fracture 50 recurrent ovarian 50 SLNB 50 vertebral fractures 50 urate levels 50 estrogen metabolism 50 bowel polyps 50 abnormal mammogram 50 prepregnancy 50 oral contraceptive pill 50 mammographic screening 50 hot flashes 50 malignant lesions 50 VaD 50 placebo controlled studies 50 abnormal cytology 50 KRAS mutations 50 NPH insulin 50 deep venous thromboses 50 dietary fiber intake 50 axillary node 50 Degarelix 50 synthetic progestin 50 varicoceles 50 prostate biopsy 50 hypercalcemia 50 PSA screening 50 letrozole 50 dysfunctional voiding 50 olaparib 50 COPAXONE R 50 anthracyclines 50 postmenopausal osteoporotic women 50 hypercholesterolemia 50 hemodialysis patients 50 mammary tumors 50 colon polyp 50 spontaneously hypertensive rats 50 thigh circumference 50 oestrogens 50 secondary hyperparathyroidism 50 ibandronate 50 ALND 50 TURP 50 sentinel lymph node biopsy 50 triiodothyronine 50 curative resection 50 epithelial ovarian 50 DHEAS 50 metastatic prostate cancer 50 conjugated estrogen 50 cerebral infarction 50 VLBW infants 50 invasive bladder 50 alendronate Fosamax 50 Stenting Trial CREST 50 potentially modifiable 50 ApoE4 50 postnatally 50 paroxetine Paxil 50 antibiotic prophylaxis 50 Baltimore Longitudinal Study 50 lipid lowering medication 50 hepatectomy 50 bone density 50 symptomatic VTE 50 genistein 50 fulvestrant 50 PSA nadir 50 precancerous cervical 50 axillary node dissection 50 lumbar spine bone 50 vaginal hysterectomy 50 differentiated thyroid 50 RE LY trial 50 SHPT 50 mucosal healing 50 prospective longitudinal 50 plasma selenium 50 HER2 expression 50 LHRH receptor positive 50 invasive ductal 50 perioperatively 50 femoral neck 50 hyperintense lesions 50 radical cystectomy 50 thrombotic events 50 colectomy 50 pre eclamptic 50 thyrotropin 50 reinfarction 50 Colorectal Cancers 50 endometrium 50 CIN2 + 50 Multivariate analyzes 50 situ LCIS 50 uterine cancers 50 intact parathyroid hormone 50 lipohypertrophy 50 painful menstrual periods 50 bowel cancers 50 lipid lowering drugs 50 Michael F. Leitzmann 50 prostate TURP 50 glomerular filtration 50 longitudinal cohort study 50 coinfection 50 femoral shaft fractures 50 colorectal carcinoma 50 androgenic alopecia 50 partial nephrectomy 50 microvascular complications 50 plasma homocysteine levels 50 venlafaxine XR 50 Neoadjuvant 50 statins 50 HER2 positive metastatic breast 50 myomectomy 50 Health Initiative Observational 50 abnormal Pap test 50 premenstrual dysphoric disorder PMDD 50 bezafibrate 50 FOLFOX4 50 Adjuvant therapy 50 Ovarian PLCO Cancer 50 antioxidant supplements 50 atazanavir 50 lowest tertile 50 plus progestin hormone 50 lobular carcinoma 50 nonmelanoma skin cancer 50 cardioprotective effects 50 Cognitive impairment 50 ziprasidone 50 squamous histology 50 FASLODEX 50 medroxyprogesterone acetate 50 prepregnancy BMI 50 corticosteroid therapy 50 chemoradiation 50 folate supplements 50 ICDs implanted 50 mg dose 50 hydroxyvitamin D 50 Subgroup analysis 50 sildenafil Viagra 50 ACCORD Lipid 50 HbA1C levels 50 underwent brachytherapy 50 trastuzumab Herceptin ® 50 clinically insignificant 50 Moderate drinkers 50 LEXIVA r 50 Observational studies 50 PUFA intake 50 BARI 2D 50 corticosteroid induced 50 posaconazole 50 monounsaturated fat 50 statin 50 undergoing androgen deprivation 50 ALISTA 50 aromatase 50 desvenlafaxine succinate 50 inflammatory polyarthritis 50 Health Initiative WHI 50 thiopurine 50 serum glucose 50 5-FU/LV 50 systemic lupus erythematosus SLE 50 mammographically 50 dietary antioxidants 50 phytoestrogens 50 benign proliferative breast 50 virologic response 50 CrCl 50 lipoatrophy 50 NIDDM 50 subclinical 50 dopaminergic therapy 50 Naresh Punjabi 50 breast tissue 50 alpha carotene 50 thromboembolic disease 50 methotrexate therapy 50 subgroup analyzes 50 cirrhotic patients 50 stimulant medications 50 adolescent females 50 hyperphenylalaninemia HPA due 50 ViaDerm hPTH #-# 50 treatment emergent AEs 50 serum GGT 50 multivariate analyzes 50 Intervention Trial 50 nifedipine 50 abnormal pap smears 50 atypical antipsychotic medications 50 waist circumferences 50 precancerous cervical lesions 50 myocardial uptake 50 fat diet 50 macronutrient intake 50 lymph node biopsies 50 biologic plausibility 50 sunitinib malate 50 ARCOXIA 50 migraineurs 50 arzoxifene 50 BENICAR HCT 50 cortisol secretion 50 hormone receptor status 50 cervical intraepithelial neoplasia 50 SCIg 50 RBP4 levels 50 prospective observational 50 thrombophilia 50 norethindrone acetate 50 IM progesterone 50 psychiatric comorbidities 50 axillary lymph node dissection 50 eosinophil count 50 serum triglyceride levels 50 osteoporotic vertebral compression fractures 50 colorectal polyp 50 renal artery stenosis 50 menopausal 50 hs CRP 50 Multicenter AIDS